

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/863,101	05/18/2001	Robert D. Mass	3118/1H146US1	9233	
9157	7590 03/14/2005		EXAMINER		
GENENTECH, INC.			HOLLERAN, ANNE L		
1 DNA WAY SOUTH SAN FRANCISCO, CA 94080			ART UNIT	PAPER NUMBER	
			1642	. 1642	
			DATE MAILED: 03/14/200	DATE MAILED: 03/14/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Application No. Applicant(s) Og/863,101 MASS, ROBERT D.	e e						
Examiner Anne Holleran The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In or event, however, may a reply be timely filled after SIX(b) MONTH's from the major day of the correction of the provision of 37 CFR 1.136(a). In or event, however, may a reply be timely filled after SIX(b) MONTH's from the major day of the control of the provision of 37 CFR 1.136(a). In or event, however, may a reply be timely filled after SIX(b) portiod for reply is applied above, the maintenant stabulary period will seply and will expire SIX(b) flowling from the realising date of this communication. Fallow to reply is specified above, the maintenant stabulary period will seply and will expire SIX (b) MONTH's from the realising date of this communication. Fallow to reply with the set or extended period for reply its patients, cause the application to become ABARDONED (SU S.C. \$ 133). Fallow to reply is specified above, the mainting date of this communication, seen if timely filed, may reduce they acred patent term adjustment. See 37 CFR 1.704(b) This action is FINAL. 2 b) MONTH This action is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4 MONTH This action is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4 MONTH This action is a condition of the proving in the application. 4 Disposition of Claims 4 MONTH This action is a condition of the proving accordance with the drawing in the proving the pro		Application No.	Applicant(s)				
Anne Holleran Antechnet He Mall Holleran Antechnet He Mall Holleran Antechnet He Mall Holleran Antechnet He Mall He Mall H		09/863,101	MASS, ROBERT D.				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address—Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions time may be evaluated under the provision of 3 of ER 1.13(6). In no event, however, may a reply be timely flied after SX (6) MONTHS from the mailing date of this communication. Extensions for reply in specified before the mailing date of this communication. Followed for reply in specified before the mailing date of this communication. Followed for reply in specified before the think these montains after the mailing date of this communication, even if timely flied, may reduce any evaluate by the delice the think these montains after the mailing date of this communication, even if timely flied, may reduce any evaluate by the state of the state that the these mains after the mailing date of this communication, even if timely flied, may reduce any evaluate principle to the polymore that the majority of the state of the communication, even if timely flied, may reduce any evaluate principle to the mailing date of this communication, even if timely flied, may reduce any evaluate principle to the mailing date of this communication, even if timely flied, may reduce any evaluate principle to the mailing date of this communication. 1) □ Responsive to communication(s) filled on @9 November 2004. 2a) □ This action is FINAL. 2b) □ This action is non-final. 3) □ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under £x parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) □ Claim(s) 21.25 and 26 is/are pending in the application. 4) □ Claim(s) 21.25 and 26 is/are allowed. Claim(s) 21.25 and 26 is/are allowed. Claim(s) 21.25 and 26 is/are rejected. 7) □ Claim(s) 21.25 and 26 is/are rejected. 7) □ Claim(s) 21.25 and 26 is/are rejected. 10 □ The drawing(s) filed on	Office Action Summary	Examiner	Art Unit				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.35(a), is no event, however, may a reply be timely filed. Extensions of time may be available under the provisions of 37 CFR 1.35(a) is no event, however, may a reply be timely filed. Extensions of timely pecified above, be maximum statutory period will apply and the statutory minimum of thinty (30) days will be considered timely. Extensions of the provision has not extended period for righy shall be the maximum statutory period will apply and use price Stx (5) MOINTIS from the mailing date of this communication. Failure to reprovision the or extended period for righy will, by statute, capable the application of the communication, even if timely filed, may reduce any searned patent term adjustment. See 37 GFR 1.704(b). Status 1) Responsive to communication(s) filed on 09 November 2004. 22) This action is FiNAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 21.25 and 26 is/are pending in the application. 4a) Of the above claim(s) is are allowed. 5) Claim(s) is/are allowed. 5) Claim(s) is/are allowed. 6) Claim(s) is/are allowed. 6) Claim(s) 21.361 26 is/are rejected. 7) Claim(s) 25 is/are objected to. 8) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) bill objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheel(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. §	·						
THE MAILING DATE OF THIS COMMUNICATION. Edanisors of time may be available under the provisions of 37 CPR 1.13(a). In no event, however, may a reply be timely filed after SX (6) MONTHS from the mailing date of this communication. If the period for reply predicts done in less than Milk (20 Mays, not Milk a studiety, minimum of thirty (30) days, will be considered timely. If the period for reply predicts done in less than Milk (20 Mays, not Milk application to the promise SX (6) MONTHS from the mailing date of this communication. Failure to reply villine the set or estended period for reply villing the application to become ABANDONED (35 U.S.C. § 13.3). Any reply received by the Office and the set of restrictions after the mailing date of this communication, even if timely filed, may reduce any certained patient term adjustment. Set 37 CFR 1.704(b). Status 1) □ Responsive to communication(s) filed on 09 November 2004. 2a) □ This action is FINAL. 2b) □ This action is non-final. 3) □ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) □ Claim(s) 21.25 and 26 is/are pending in the application. 4a) Of the above ctaim(s) is/are withdrawn from consideration. 5) □ Claim(s) 21 and 26 is/are allowed. 6) □ Claim(s) 25 is/are objected to. 8) □ Claim(s) 25 is/are objected to. 8) □ The specification is objected to by the Examiner. 10 □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTC-152. Priority under 35 U.S.C. § 119 12) □ Acknowledgment is made of a claim for foreign prior		pears on the cover sheet with the c	orrespondence address				
1)⊠ Responsive to communication(s) filed on 09 November 2004. 2a)□ This action is FINAL. 2b)⊠ This action is non-final. 3)□ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4)☑ Claim(s) 21.25 and 26 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5)□ Claim(s) is/are allowed. 6)☑ Claim(s) 21 and 26 is/are rejected. 7)☑ Claim(s) 25 is/are objected to. 8)□ Claim(s) are subject to restriction and/or election requirement. Application Papers 9)□ The specification is objected to by the Examiner. 10)□ The drawing(s) filed on is/are: a)□ accepted or b)□ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11)□ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12)□ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)□ All b)□ Some * c)□ None of: 1.□ Certified copies of the priority documents have been received. 2.□ Certified copies of the priority documents have been received in Application No 3.□ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing	36(a). In no event, however, may a reply be tim y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
2a] This action is FINAL. 2b)⊠ This action is non-final. 3 Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4)	Status						
2a] This action is FINAL. 2b)⊠ This action is non-final. 3 Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4)	1) Responsive to communication(s) filed on 09 N	lovember 2004.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 21.25 and 26 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 25 is/are objected to. 8) Claim(s) 25 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some *c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received.							
4) Claim(s) 21.25 and 26 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 21 and 26 is/are rejected. 7) Claim(s) 25 is/are objected to. 8) Claim(s) 25 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) 21 and 26 is/are rejected. 7) □ Claim(s) 25 is/are objected to. 8) □ Claim(s) 25 is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	Disposition of Claims						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) <u>21 and 26</u> is/are rejected. 7) ☐ Claim(s) <u>25</u> is/are objected to. 	wn from consideration.	·				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) ☑ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)	Application Papers						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	9) The specification is objected to by the Examine	er.					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date. Paper No(s)/Mail Date.							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date	Priority under 35 U.S.C. § 119	.*					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date	12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau	is have been received. is have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date		_					
2) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 1/2/2004 > 1/3/2004 (PTO-152) Other:							
	2) Involce of Dransperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date デルン レード テルドルング						

Art Unit: 1642

DETAILED ACTION

- 1. The amendment filed November 9, 2004 is acknowledged.
- 2. Claims 21, 25 and 26 are pending and examined on the merits.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections Withdrawn:

- 4. The rejection of claim 25 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in view of the amendment.
- 5. The rejection of claims 21, 25 and 26 under 35 U.S.C. 103(a) as being unpatentable over Baselga I (Baselga, Journal of Cinical Oncology, 14: 737-744, 1996; cited in IDS) or Baselga II (Baselga, Semin. Oncol., 26(4): 87-83, 1999) in view of either Pauletti (previously identified as "Godolphin"; Oncogene, 13: 63-72, 1996; of record) or Persons (Annals of Clincial and Laboratory Science, 30: 41-48, 2000, Jan.; cited in IDS) is withdrawn in view of the amendment changing the scope of the claims to a method for treating patients that express HER2 at 0 or 1+

Art Unit: 1642

level by immunohistochemistry and also have a HER2 gene amplification. The prior art of record does not teach or fairly suggest claims with this limitation.

New Grounds of Rejection:

Claim Rejections - 35 USC § 112

6. Claims 21 and 26 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods where the HER2 antibody is huMAb4D5-8, does not reasonably provide enablement for methods for identifying and treating patients disposed to respond favorably to any HER2 antibody. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation would be required to practice the full scope of the claimed inventions are: 1) quantity of experimentation necessary; 2) the amount of direction or guidance presented in the specification; 3) the presence or absence of working examples; 4) the nature of the invention; 5) the state of the prior art; 6) the relative skill of those in the art; 7) the predictability or unpredictability of the art; and 8) the breadth of the claims. See In re Wands, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

The claimed inventions are drawn to methods for identifying and treating breast cancer patients disposed to respond favorably to a HER2 antibody, wherein the patient's tumor cells express HER2 at 0 or 1+ level by immunohistochemistry, comprising detecting HER2 gene amplification in tumor cells in a tissue sample from the patient and treating the patient with HER2 gene amplification. The basis for the claimed methods is that the specification provides

Art Unit: 1642

data showing that those patients having HER-2 amplification respond favorably to Herceptin when compared to patients who do not have a HER2 gene amplification.

The prior art has recognized that HER2 status is a predictor of response of response to Herceptin therapy and that HER2 status may be measured by detecting HER2 protein overexpression by immunohistochemical methods or by detection of HER2 gene amplification. The prior art favored the use of immunohistochemical methods for measuring HeR2 status, because the test was considered more practical in a clinical trial setting (Jacobs, J. Clinical Oncol, 17(7): 1974-1982, 1999). Currently, it is accepted that HER2 status should be assessed before beginning a treatment with Herceptin, and two methods that may be used are a measure of gene amplification by FISH or a measure of HER2 protein expression by immunohistochemistry with a HER-2 specific antibody (Nahta, Clinical Cancer Research, 9: 5078-5084, 2003; page 5078, 2nd col.). However, there are no teachings in the prior art demonstrating an association between HER2 status (either protein overexpression or gene amplification) and a favorable response to anti-HER2 antibodies other than Herceptin. Furthermore, the mechanism by which Herceptin causes regression of breast tumors is not completely understood (Nahta, Clinical Cancer Research, 9, 5078-5084; page 5079). Also, there appears to be some anti-HER2 antibodies (e.g. 2C4) that are effective on breast tumors that express normal levels of HER2 and do not overexpress HER2 (Nahta, Clinical Cancer Research, 9, 5078-5084; page 5080).

The specification provides data that demonstrates that favorable response to Herceptin is linked to HER2 gene amplification, and fails to demonstrate such a correlation between a response to any other anti-HER2 antibody and HER2 gene amplification. The prior art also fails to demonstration an association between favorable outcome with any other anti-HER2 antibody

nator rumber: 02/003

Art Unit: 1642

and HER2 gene amplification. Thus, to practice the full scope of the claimed inventions further experimentation would have to be done by a skilled worker to discover if an association exists between favorable response to treatment with an anti-HER2 antibody and gene amplification. This further experimentation is undue experimentation because it is unpredictable whether such an association would be discovered. Therefore, the specification presents an invitation for further experimentation, where the outcome of the further experimentation is not predictable. This is in contrast to the situation in Wands (858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988)), where the outcome of the further experimentation was predictable, i.e. that someone in possession of a protein would be able to make a monoclonal antibody to that protein.

Because of the narrow scope of the teachings of the specification, where the specification is directed to demonstrating an association between gene amplification and response to Herceptin therapy, and because the prior art fails to show that an association between gene amplification and response to any other anti-HER2 antibody, and because the discovery of such an association is unpredictable for other anti-HER2 antibodies, the full scope of the claims, where the claims are directed to identifying and treating a patient disposed to respond favorably to any anti-HER2 antibody, is not enabled by the specification.

Conclusion

No claim is allowed. Claim 25 is objected to for depending from a rejected claim.

Any inquiry concerning this communication or earlier communications from the Office should be directed to Anne Holleran, Ph.D. whose telephone number is (571) 272-0833. Examiner Holleran can normally be reached Monday through Friday, 9:30 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew, can be reached at (571) 272-0787.

Art Unit: 1642

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at telephone number (703) 571-1600.

Anne L. Holleran Patent Examiner March 9, 2005

ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER

03/11/2005